Sign in

ZSQR on Nasdaq

Z Squared Inc.

Z Squared Inc. is an American finance services company based in Fort Lauderdale.2 Its shares trade on Nasdaq under the symbol ZSQR.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Magic Empire Global Ltd, Brera Holdings PLC or Grande Group Ltd/HK, or pick any stock.

  • TickerZSQR on Nasdaq2
  • IndustryFinance Services2
  • HeadquartersFort Lauderdale, United States2
  • Incorporated inDE3
  • Business address550 South Andrews Ave., Ste #700, Fort Lauderdale, Fl 333013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5299004UXP8XTVR4KR352
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 70938312

See how the biggest companies compare on our leaderboards

Therapeutics, Inc., which we now continue to operate as our wholly owned subsidiary.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

86.7%Gross margin6
-956.9%Operating margin6
-874.3%Net margin6
-87.9%Return on equity6
0.01×Debt to equity6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Advertising Campaigns brought in 92% of the revenue Z Squared Inc. broke down this way in fiscal 2025.

  1. Advertising Campaigns$1.3M692%
  2. Webinar Services$112.5K68%
Products and services by year
Products and services20242025
Advertising Campaigns$1.3M
Webinar Services$112.5K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue12¢$180.6K
  • Research and development88¢$1.3M

Out of $1.4M in revenue.6 The company lost money this year.

Financial statements

Revenue7896$1.4M in 2025+1717% since 2021
0$500.0K$1.0M$1.5M2021: $75.0K$75.0K20212022: $0$020222023: $0$020232024: $0$020242025: $1.4M$1.4M2025
Gross profit7896$1.2M in 2025+1477% since 2021
0$500.0K$1.0M$1.5M2021: $75.0K$75.0K20212022: $0$020222023: $0$020232024: $0$020242025: $1.2M$1.2M2025
Operating income10117896-$13.0M in 2025+583763% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$2.2K-$2.2K20192020: -$68.4K-$68.4K2020+2963%2021: -$14.0M-$14.0M2021+20426%2022: -$34.2M-$34.2M2022+143%2023: -$21.5M-$21.5M2023−37%2024: -$10.1M-$10.1M2024−53%2025: -$13.0M-$13.0M2025+30%
Net income10117896-$11.9M in 2025+533338% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$2.2K-$2.2K20192020: -$17.3M-$17.3M2020+773390%2021: -$13.4M-$13.4M2021−22%2022: -$37.6M-$37.6M2022+179%2023: -$21.3M-$21.3M2023−43%2024: -$10.7M-$10.7M2024−50%2025: -$11.9M-$11.9M2025+12%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Total sales$1.4M$0
Cost of goods$180.6K$0
Gross profit$1.2M$0
Research and development expense$1.3M$2.3M
Salary expense$1.7M$1.7M
Amortization expense$1.0M$1.0M
Professional services expense$7.8M$3.0M
Stock based compensation expense$1.2M$1.1M
General and administrative expenses$1.1M$945.6K
Selling and marketing expense$105.0K$0
Total cost of operations$14.2M$10.1M
LOSS FROM OPERATIONS-$13.0M-$10.1M
Interest expense-$96.7K-$246.1K
Interest income$116.5K$234.7K
Amortization of debt discount-$545.6K-$216.2K
Gain on forfeiture of customer deposit$115.0K$0
Other income (expense), net$7.0K-$16.4K
Unrealized gain on marketable securities$76.6K$0
Unrealized loss on investments-$163.5K$0
Loss on write down of assets$0-$37.3K
Gain (loss) on extinguishment of debt$159.0K-$200.0K
Change in fair value of derivative liabilities$1.1M-$341.7K
TOTAL OTHER INCOME (EXPENSE), net$766.3K-$822.9K
LOSS BEFORE INCOME TAXES-$12.3M-$10.9M
PROVISION FOR INCOME TAXES (BENEFIT)$0$0
NET LOSS-$12.3M-$10.9M
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS-$360.2K-$197.0K
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS-$11.9M-$10.7M
Loss per share, basic-$2.81-$5.56
Loss per share, fully diluted-$2.81-$5.56
Weighted average number of common shares outstanding, basic4.2M shares1.9M shares
Weighted average number of common shares outstanding, diluted4.2M shares1.9M shares

Compare Z Squared Inc. with another company

Corporate structure

Z Squared Inc. sits at the top of its group. 5 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Z Squared Inc.

  • Z Squared Inc. fort lauderdale, Florida, United States
    • Coeptis Pharmaceuticals LLC Subsidiary · Pennsylvania, United States
    • Coeptis Therapeutics, Inc. Subsidiary · Delaware, United States
    • GEAR Therapeutics, Inc. Subsidiary · Florida, United States
    • SNAP Biosciences, Inc. Subsidiary · Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Z Squared Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$25.2K9 Dec 31, 2024$25.2K9 Dec 31, 20230%
Accumulated depreciation$14.8K9 Dec 31, 2024$13.9K9 Dec 31, 2023+6.1%
Property and equipment, net$9.9K6 Dec 31, 2025$10.5K6 Dec 31, 2024−5.6%
Operating-lease assets (leased space)$18.4K6 Dec 31, 2025$59.8K6 Dec 31, 2024−69.2%

Investments

ItemLatestA year beforeChange
Marketable securities, current$676.6K6 Dec 31, 2025$06 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$361.2K6 Dec 31, 2025$541.9K6 Dec 31, 2024−33.3%

Properties, in its own words

Our principal place of business is located at 105 Bradford Street, Suite 420, Wexford, Pennsylvania 15090, which we lease. The lease is scheduled to expire on May 31, 2026.

We do not own any properties or land.

The rest of Item 2

We believe our facilities are adequate and suitable for our current needs and that, should it be needed, suitable additional or alternative space will be available.

Item 2 of the 10-K filed Mar 19, 2026.5

Leadership

Who has led Z Squared Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert Striar2020
  2. David Mehalick2022–2026
  3. David Elias Halabu2026–now
  4. Michelle Ellen Burke2026–now

President

  1. David Mehalick2022–now

Chief financial officer

  1. Chris Calise2020
  2. Christine Elise Sheehy2022–2023
  3. Brian Cogley2024–now
2025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerColleen Delaney named Jun 27, 202437
  • DirectorChristopher Cochran named Aug 7, 202538
  • DirectorChristopher Maria Cochran named Jun 27, 202437

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Coeptis Pharmaceuticals LLC Pennsylvania4
  • Coeptis Pharmaceuticals, Inc. Delaware4
  • Coeptis Therapeutics, Inc. Delaware4
  • GEAR Therapeutics, Inc. Florida4
  • SNAP Biosciences, Inc. Florida4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Coeptis Therapeutics Holdings, Inc.Jun 22, 2022 to Apr 28, 20263
  • Bull Horn Holdings Corp.Feb 21, 2019 to Oct 28, 20223

Timeline

  1. Sep 14, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares39
  2. Sep 10, 20268-K Bylaws or fiscal year changed40
  3. Aug 26, 20268-K Executive or director change41
  4. Aug 4, 20268-K Entered a material agreement; Ended a material agreement; Unregistered sale of shares42
  5. Jul 22, 20268-K Ended a material agreement; Regulation FD disclosure43
  6. Jul 10, 20268-K Entered a material agreement44
  7. Jul 7, 20268-K Entered a material agreement45
  8. Jun 30, 20268-K Executive or director change; Regulation FD disclosure46
  9. Jun 29, 20268-K Regulation FD disclosure; Other events47
  10. Jun 26, 20268-K Entered a material agreement; Regulation FD disclosure48
  11. Jun 4, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure49
  12. Jun 1, 20268-K Financial statements and exhibits50
  13. Apr 29, 2026New chief executive Michelle Ellen Burke becomes CEO15
  14. Apr 29, 2026New chief executive David Elias Halabu becomes CEO14
  15. Nov 7, 2022New chief executive David Mehalick becomes CEO16
  16. Oct 27, 2022Founded Z Squared Inc. is founded2
  17. Oct 30, 2020New chief executive Robert Striar becomes CEO17

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202651

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

307 filings to the SEC since October 2021: 9 annual reports, 20 quarterly reports, 60 major events, 75 insider forms, 24 large holders, 3 private raises, 116 other. The latest 20:

  1. Oct 5, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 2, 20264 EDGAR
  4. Oct 2, 20264 EDGAR
  5. Oct 2, 20264 EDGAR
  6. Oct 2, 20264 EDGAR
  7. Oct 2, 20264 EDGAR
  8. Oct 2, 20264/A EDGAR
  9. Sep 14, 20268-K EDGAR
  10. Sep 10, 20268-K EDGAR
  11. Aug 26, 20268-K EDGAR
  12. Aug 25, 20264 EDGAR
  13. Aug 21, 2026S-8 EDGAR
  14. Aug 20, 20264 EDGAR
  15. Aug 13, 202610-Q EDGAR
  16. Aug 4, 20268-K EDGAR
  17. Jul 31, 2026SCHEDULE 13G/A EDGAR
  18. Jul 27, 2026POSASR EDGAR
  19. Jul 22, 20268-K EDGAR
  20. Jul 10, 20268-K EDGAR

The 307 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 11 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 18, 2026Schadel Christopher RyanChief Marketing OfficerBuy1,000$3.92$3.9KForm 4
Jan 12, 2024DeSilva TaraDirectorBuy2,266$0.58$1.3KForm 4
Jan 10, 2024Cogley BrianChief Financial OfficerBuy5,000$0.67$3.4KForm 4
Jan 8, 2024Mehalick DavidCEO and PresidentBuy20,004$0.66$13.3KForm 4
Jan 5, 2024Yerace Daniel AlexanderVP OperationsBuy10,850$0.69$7.5KForm 4
Jan 5, 2024Salkind GeneDirectorBuy11,600$0.69$8.0KForm 4
Jan 5, 2024Mehalick DavidCEO and PresidentBuy5,050$0.69$3.5KForm 4
Jan 5, 2024Cochran Christopher P.DirectorBuy7,000$0.77$5.4KForm 4
Aug 29, 2023Salkind GeneDirectorBuy4,006$1.01$4.0KForm 4
Aug 25, 2023Salkind GeneDirectorBuy28,638$0.91$26.1KForm 4
Aug 23, 2023Calise ChrisDirectorBuy11,582$0.94$10.9KForm 4
May 4, 2022Harraden Circle Investors GP, LP10% ownerSale85,305$10.11$862.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2023Colleen Delaney$360.0K68
2023Daniel Yerace$360.0K68
2023David Mehalick$360.0K68
2023Brian Cogley$200.0K$208.0K68
2023Christine Sheehy*$151.0K68
2022ChairmanCEO and President$286.6K$361.6K68
2022Vice President of Operations$285.3K$360.3K68
2022Former Chief Financial Officer$151.0K$226.0K68

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$10.3M 2023–2025
Money received by yearMoney received by year, 2023–2025: $10.3M in all. Private raises (Form D) $10.3M.$0$2M$4M$6M2023 · Private raises (Form D): $2.0M20232024 · Private raises (Form D): $4.3M20242025 · Private raises (Form D): $4.0M2025
Figures by year
YearPrivate raises (Form D)Total
2025$4.0M$4.0M
2024$4.3M$4.3M
2023$2.0M$2.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jul 24, 2025Raised $4 million in a private offering of equity38 Form D: $5 million offered in all Form D
  2. Jun 14, 2024Raised $4.3 million in a private offering of equity37 Form D: $10 million offered in all Form D
  3. Oct 26, 2023Raised $2 million in a private offering of equity69 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 44. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.2,520,856$26.7M0.0%New
Vanguard Capital Management LLC1,670,495$17.7M0.0%New
Geode Capital Management, LLC713,196$7.5M0.0%New
Northern Trust Corp346,687$3.7M0.0%New
Vanguard Portfolio Management LLC303,288$3.2M0.0%New
Vanguard Fiduciary Trust Co128,391$1.4M0.0%New
Nuveen, LLC104,189$1.1M0.0%New
Charles Schwab Investment Management Inc103,522$1.1M0.0%New
Bank of New York Mellon Corp91,603$969.2K0.0%New
United Capital Financial Advisors, LLC86,062$910.5K0.0%New
UBS Group AG70,148$742.2K0.0%New
Rhumbline Advisers49,649$525.3K0.0%New
Deutsche Bank Ag\43,667$462.0K0.0%New
Wells Fargo & Company/mn40,056$423.8K0.0%New
Wellington Management Group Llp33,100$350.2K0.0%New
MetLife Investment Management, LLC26,305$278.3K0.0%New
Bank Of America Corp /de/25,189$266.5K0.0%New
Invesco Ltd.23,857$252.4K0.0%New
Jpmorgan Chase & Co19,475$227.3K0.0%New
Citigroup Inc20,602$218.0K0.0%New
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.20,134$213.0K0.0%New
Morgan Stanley16,695$176.6K0.0%New
Sagespring Wealth Partners, LLC15,708$166.2K0.0%New
New York State Common Retirement Fund15,400$162.9K0.0%New
Alliancebernstein L.P.13,160$139.2K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Z Squared Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARZ Squared Inc.1
  • CIK0001759186
  • Employer ID (EIN)98-14659525
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)6199 Finance Services1
  • SEC reviewing officeOffice of Crypto Assets, Division of Corporation Finance1
  • Business address550 South Andrews Ave., Ste #700, Fort Lauderdale, FL 333011
  • Phone954-400-99941
  • Shares outstanding53,000,397 as of Aug 11, 202613
  • Public float$28.2M as of Jun 30, 20255
  • AuditorAstra Audit and Advisory LLC, Tampa, Florida PCAOB ID 6920; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceFeb 21, 20191
  • Filings374 in all: 8-K (65), 4 (60), 424B3 (33), 3 (28), CORRESP (20), 10-Q (18), SC 13G (14), SC 13G/A (14)1
    All 43 form types

    UPLOAD (12), S-4/A (11), S-1/A (10), EFFECT (9), 10-K (6), S-1 (6), 10-K/A (5), 10-Q/A (5), DEF 14A (5), NT 10-Q (5), PRE 14A (4), SCHEDULE 13G (4), 144 (3), 424B4 (3), 425 (3), D (3), DEFA14A (3), DRS/A (3), 25-NSE (2), POS AM (2), S-1MEF (2), S-4 (2), SCHEDULE 13G/A (2), 4/A (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), NT 10-K (1), POSASR (1), S-3ASR (1), S-8 (1), SC 13D (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 19, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Nov 14, 2024
    Latest 8-K (8-K) Sep 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareCOEPNasdaq
Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole shareCOEPWNasdaq

From the cover page of the 10-K filed Mar 19, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Z Squared Inc. names in Item 1A of its 10-K filed Mar 19, 2026: 36 risks under these headings, as written.5

  • Throughout this section, references to “Company,” “Coeptis,” “we,” “us,” “our” and similar terms refer collectively to Coeptis Therapeutics Holdings, Inc., a Delaware corporation, and its operating subsidiaries, as the context so requires.
  • Risks Related to the Development and Regulatory Approval of Our Product Candidates
  • Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes. Results of previous pre-clinical studies and clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or other regulatory authorities.
  • If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue.
  • The design or our execution of clinical trials may not support regulatory approval.
  • We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which could delay or prevent the start of clinical trials for our product candidates.
  • General Risks
  • There is a substantial doubt about our ability to continue as a going concern.
  • We have incurred significant losses in prior periods, and losses in the future could cause the quoted price of our Common Stock to decline or have a material adverse effect on our financial condition, our ability to pay its debts as they become due, and on its cash flows.
  • If we are unable to manage future expansion effectively, our business may be adversely impacted.
  • The Company’s ability to be successful will depend upon the efforts of the Company’s Board and our key personnel and the loss of such persons could negatively impact the operations and profitability of the Company’s business.
  • If we are unable to recruit and retain key personnel, our business may be harmed.
The other 26 risks
  • Our business plan is not based on independent market studies.
  • Our Board of Directors may change our policies without shareholder approval.
  • We need to obtain financing in order to continue our operations and pursue strategic transactions.
  • We currently do not have sufficient cash to fully implement our business plan.
  • We have a limited operating history and a history of operating losses, and expect to incur significant additional operating losses.
  • The drug development and approval process is uncertain, time-consuming and expensive.
  • We will be required to sustain and further build our intellectual property rights.
  • We will be required to comply with our obligations in our intellectual property licenses and other agreements with third parties.
  • Patent litigation or other litigation in connection with our intellectual property rights may lead to publicity that may harm our reputation and the value of our common stock may decline.
  • Protecting and defending against intellectual property claims may have a material adverse effect on our business.
  • Our competitors and potential competitors may develop products and technologies that make ours less attractive or obsolete.
  • Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for us.
  • The Company’s business and operations could be negatively affected if it becomes subject to any securities litigation or shareholder activism, which could cause the Company to incur significant expense, hinder execution of business and growth strategy and impact its stock price.
  • Risk Related to Regulation
  • The regulatory approval process is costly and lengthy, and we may not be able to successfully obtain all required regulatory approvals.
  • Even if we receive regulatory approvals for marketing our product candidates, if we fail to comply with continuing regulatory requirements, we could lose our regulatory approvals, and our business would be adversely affected.
  • Even if we are able to obtain regulatory approvals for any of our product candidates, if they exhibit harmful side effects after approval, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.
  • Healthcare reform measures could adversely affect our business.
  • Federal legislation may increase the pressure to reduce prices of pharmaceutical products paid for by Medicare, which could adversely affect our revenues, if any.
  • Federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any.
  • Failure to obtain regulatory and pricing approvals in foreign jurisdictions could delay or prevent commercialization of our products abroad.
  • Risks Related to Our Organization and Structure
  • Our holding company structure makes us dependent on our subsidiaries for our cash flow and could serve to subordinate the rights of our shareholders to the rights of creditors of our subsidiaries, in the event of an insolvency or liquidation of any such subsidiary.
  • Delaware law and the Amended and Restated Certificate of Incorporation and Bylaws contain certain provisions, including anti-takeover provisions that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.
  • The Amended and Restated Certificate of Incorporation designates a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between the Company and its stockholders, which could limit the Company’s stockholders’ ability to choose the judicial forum for disputes with the Company or its directors, officers, or employees.
  • Risks Related to Our Capital Requirements and Capital Structure
  • Nasdaq may delist the Company’s securities from trading on its exchange, which could limit investors’ ability to make transactions in the Company’s securities and subject the Company to additional trading restrictions.
  • If securities or industry analysts do not publish research or reports about our business or publish negative reports about our business or our industry, the trading price and volume of our securities could decline.
  • We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies may make our securities less attractive to investors.

Legal proceedings

We are from time to time subject to litigation and other proceedings that arise in the ordinary course of our business. Subject to the inherent uncertainties of litigation and although no assurances are possible, we believe that there are no pending lawsuits or claims that, individually or in the aggregate, will have a material adverse effect on our business, financial condition or our yearly results of operations.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69